AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer—2026 Update / Andreas Hartkopf, Ute-Susann Albert, Rupert Bartsch, Ingo Bauerfeind, Maggie Banys-Paluchowski, Vesna Bjelic-Radisic, Jens-Uwe Blohmer, Peter Dall, Eva Maria Fallenberg, Peter A. Fasching, Michael Friedrich, Oleg Gluz, Nadia Harbeck, Jörg Heil, Juliane Hörner-Rieber, Jens Huober, Wolfgang Janni, Hans-Heinrich Kreipe, David Krug, Thorsten Kühn, Sherko Kümmel, Sibylle Loibl, Diana Lüftner, Michael Patrick Lux, Nicolai Maass, Marion Tina van Mackelenbergh, Christoph Mundhenke, Tjoung-Won Park-Simon, Mattea Reinisch, Toralf Reimer, Kerstin Rhiem, Achim Rody, Andreas Schneeweiss, Florian Schütz, Hans-Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Marc Thill, Michael Untch, Isabell Witzel, Achim Wöckel, Rachel Wuerstlein, Nina Ditsch, Tanja Fehm, Volkmar Müller, Marcus Schmidt

Related documents

• Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer#852308
• Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment#896132
• Tissue Procurement Protocol for Patients Undergoing Treatment for Early-Stage Breast Cancer#1124640
• Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer#887870
• A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer#874152